An empirical phase diagram approach to investigate conformational stability of "second-generation" functional mutants of acidic fibroblast growth factor-1

被引:22
作者
Alsenaidy, Mohammad A. [2 ]
Wang, Tingting [2 ]
Kim, Jae Hyun [3 ]
Joshi, Sangeeta B. [2 ]
Lee, Jihun [1 ]
Blaber, Michael [1 ]
Volkin, David B. [2 ]
Middaugh, C. Russell [2 ]
机构
[1] Florida State Univ, Dept Biomed Sci, Tallahassee, FL 32306 USA
[2] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[3] Univ Kansas, Bioengn Program, Lawrence, KS 66047 USA
关键词
FGF-1; stability; heparin; EPDs; structure; conformation; circular dichroism; fluorescence; light scattering; HUMAN FIBROBLAST-GROWTH-FACTOR-1; HALF-LIFE; COMPARABILITY; HEPARIN; FORMULATION; PEGYLATION; ANTIBODIES; MUTATIONS; SEQUENCE; THERAPY;
D O I
10.1002/pro.2008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acidic fibroblast growth factor-1 (FGF-1) is an angiogenic protein which requires binding to a polyanion such as heparin for its mitogenic activity and physicochemical stability. To evaluate the extent to which this heparin dependence on solution stability could be reduced or eliminated, the structural integrity and conformational stability of 10 selected FGF-1 mutants were examined as a function of solution pH and temperature by a series of spectroscopic methods including circular dichroism, intrinsic and extrinsic fluorescence spectroscopy and static light scattering. The biophysical data were summarized in the form of colored empirical phase diagrams (EPDs). FGF-1 mutants were identified with stability profiles in the absence of heparin comparable to that of wild-type FGF-1 in the presence of heparin while still retaining their biological activity. In addition, a revised version of the EPD methodology was found to provide an information rich, high throughput approach to compare the effects of mutations on the overall conformational stability of proteins in terms of their response to environmental stresses such as pH and temperature.
引用
收藏
页码:418 / 432
页数:15
相关论文
共 46 条
[1]  
[Anonymous], 2000, Circular Dichroism: Principles and Applications
[2]   Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation [J].
Basu, Amartya ;
Yang, Karen ;
Wang, Maoliang ;
Liu, Sam ;
Chintala, Ramesh ;
Palm, Thomas ;
Zhao, Hong ;
Peng, Ping ;
Wu, Dechun ;
Zhang, Zhenfan ;
Hua, Jack ;
Hsieh, Ming-Ching ;
Zhou, John ;
Petti, Gerald ;
Li, Xiguang ;
Janjua, Ahsen ;
Mendez, Magda ;
Liu, Jun ;
Longley, Clifford ;
Zhang, Zhihua ;
Mehlig, Mary ;
Borowski, Virna ;
Viswanathan, Manickam ;
Filpula, David .
BIOCONJUGATE CHEMISTRY, 2006, 17 (03) :618-630
[3]   X-ray crystal structure of human acidic fibroblast growth factor [J].
Blaber, M ;
DiSalvo, J ;
Thomas, KA .
BIOCHEMISTRY, 1996, 35 (07) :2086-2094
[4]   Symmetric primary and tertiary structure mutations within a symmetric superfold: A solution, not a constraint, to achieve a foldable polypeptide [J].
Brych, SR ;
Dubey, VK ;
Bienkiewicz, E ;
Lee, J ;
Logan, TM ;
Blaber, M .
JOURNAL OF MOLECULAR BIOLOGY, 2004, 344 (03) :769-780
[5]   Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a β-trefoil [J].
Brych, SR ;
Blaber, SI ;
Logan, TM ;
Blaber, M .
PROTEIN SCIENCE, 2001, 10 (12) :2587-2599
[6]   PEGylated antibodies and antibody fragments for improved therapy: a review [J].
Chapman, AP .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :531-545
[7]   Characterizing biological products and assessing comparability following manufacturing changes [J].
Chirino, AJ ;
Mire-Sluis, A .
NATURE BIOTECHNOLOGY, 2004, 22 (11) :1383-1391
[8]   Naked plasmid DNA encoding fibroblast growth factor type I for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial [J].
Comerota, AJ ;
Throm, RC ;
Miller, KA ;
Henry, T ;
Chronos, N ;
Laird, J ;
Sequeira, R ;
Kent, CK ;
Bacchetta, M ;
Goldman, C ;
Salenius, JP ;
Schmieder, FA ;
Pilsudski, R .
JOURNAL OF VASCULAR SURGERY, 2002, 35 (05) :930-936
[9]   THE STRUCTURE OF HUMAN ACIDIC FIBROBLAST GROWTH-FACTOR AND ITS INTERACTION WITH HEPARIN [J].
COPELAND, RA ;
JI, HL ;
HALFPENNY, AJ ;
WILLIAMS, RW ;
THOMPSON, KC ;
HERBER, WK ;
THOMAS, KA ;
BRUNER, MW ;
RYAN, JA ;
MARQUISOMER, D ;
SANYAL, G ;
SITRIN, RD ;
YAMAZAKI, S ;
MIDDAUGH, CR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1991, 289 (01) :53-61
[10]   HYPOTENSIVE ACTIVITY OF FIBROBLAST GROWTH-FACTOR [J].
CUEVAS, P ;
CARCELLER, F ;
ORTEGA, S ;
ZAZO, M ;
NIETO, I ;
GIMENEZGALLEGO, G .
SCIENCE, 1991, 254 (5035) :1208-1210